0000950170-24-013350.txt : 20240209
0000950170-24-013350.hdr.sgml : 20240209
20240209165631
ACCESSION NUMBER: 0000950170-24-013350
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240207
FILED AS OF DATE: 20240209
DATE AS OF CHANGE: 20240209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zeng Ling
CENTRAL INDEX KEY: 0001824252
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40657
FILM NUMBER: 24615850
MAIL ADDRESS:
STREET 1: C/O DICERNA PHARMACEUTICALS, INC.
STREET 2: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Omega Therapeutics, Inc.
CENTRAL INDEX KEY: 0001850838
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 140 FIRST STREET, SUITE 501
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: (617) 949-4360
MAIL ADDRESS:
STREET 1: 140 FIRST STREET, SUITE 501
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
ownership.xml
4
X0508
4
2024-02-07
0001850838
Omega Therapeutics, Inc.
OMGA
0001824252
Zeng Ling
C/O OMEGA THERAPEUTICS, INC.
140 FIRST STREET, SUITE 501
CAMBRIDGE
MA
02141
false
true
false
false
See Remarks
false
Stock Option (Right to Buy)
3.59
2024-02-07
4
A
false
125000
0.00
A
2034-02-06
Common Stock
125000
125000
D
The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Chief Legal and Administrative Officer
/s/ Barbara Chan as Attorney-in-Fact for Ling Zeng
2024-02-09